Stock results analysis for Sector - Pharmaceuticals & Biotechnology for Q3 FY25-26 ending Dec 31, 2025
Analysis of which stocks have performed the best and worst in Sector - Pharmaceuticals & Biotechnology for Q3 FY25-26 on the basis of sales/revenues, profits and profit margins. Only companies which have declared results in the current quarter are considered.
3
POSITIVE PROFIT GROWTH
2
NEGATIVE PROFIT GROWTH
0
NEUTRAL PROFIT GROWTH
10.4
%
TOTAL REVENUE GROWTH
19.3
%
TOTAL EBIDT GROWTH
14.2
%
TOTAL OPER. PROFIT GROWTH
Positive
Negative
Pending
| Stock | Last Result Updated | Market Capitalization | Current Price | Operating Revenue Qtr | Revenue Growth Qtr YoY % | Revenue Surprise Qtr % | Net Profit Qtr | Net Profit Qtr Growth YoY % | Net Profit Surprise Qtr % | Operating Profit Qtr | Operating Profit Growth Qtr YoY % | EBITDA Qtr | EBITDA Qtr growth YoY % | Operating Profit Margin Qtr % | Operating Profit Qtr Margin% YoY Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| J B Chemicals | 16-Jan-2026 |
29826.35
|
1904.00
|
1064.72
|
10.51
|
0.00
|
197.89
|
21.79
|
-
|
295.82
|
16.23
|
314.10
|
19.65
|
27.78
|
1.37
|
| Mangalam Drugs | 15-Jan-2026 |
74.39
|
47.00
|
58.49
|
-34.07
|
-
|
-9.84
|
-864.34
|
-
|
-1.43
|
-116.33
|
-1.32
|
-114.83
|
-2.45
|
-12.33
|
| Genomic Valley Biotech | 15-Jan-2026 |
7.61
|
24.91
|
0.05
|
-77.28
|
-
|
0.01
|
-93.23
|
-
|
0.01
|
-92.72
|
0.01
|
-92.74
|
22.64
|
-48.01
|
| Bajaj Healthcare | 16-Jan-2026 |
1235.22
|
391.10
|
161.22
|
31.30
|
-
|
15.67
|
33.72
|
-
|
30.68
|
41.78
|
31.90
|
53.62
|
19.03
|
1.41
|
| Trident Lifeline | 17-Jan-2026 |
361.90
|
306.75
|
25.71
|
117.40
|
-
|
4.30
|
54.44
|
-
|
5.10
|
24.97
|
9.72
|
109.67
|
19.82
|
-14.66
|
